Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients July 16, 2026 8:00 AM EDTCompany...

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients July 16, 2026 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Eugene Sullivan - Chief Product Strategy Officer Martina Flammer - Chief Medical Officer Conference Call Participants Raymond Benza Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Ritu Baral - TD Cowen, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Leonid Timashev - RBC Capital Markets, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Faisal Khurshid - Jefferies LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Jason Zemansky - BofA Securities, Research Division Jasmine Fels - Barclays Bank PLC, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Presentation Operator Thank you for standing by, and welcome to the Insmed 12-month results from ongoing open-label extension study of TPIP in PAH patients Conference Call.

[Operator Instructions] I'd now like to turn the call over to Bryan Dunn, Head of Investor Relations. You may begin. Bryan Dunn Vice President of Investor Relations Thank you, Rob.

Good day, everyone, and welcome to today's conference call to discuss the 12-month results from our ongoing open-label extension study of TPIP in patients with PAH. Before we start, please note that today's call may include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed.

Please refer to our SEC filings for more information. I'm joined today by Will Lewis, Chair and Chief Executive Officer; and Gene Sullivan, Chief Product Strategy Officer. The call will begin with some opening remarks